Cargando…
Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic
BO-112 is a poly I:C-based viral mimetic that exerts anti-tumor efficacy when intratumorally delivered in mouse models. Intratumoral BO-112 synergizes in mice with systemic anti-PD-1 mAbs and this combination has attained efficacy in PD1-refractory melanoma patients. We sought to evaluate the anti-t...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078127/ https://www.ncbi.nlm.nih.gov/pubmed/37035637 http://dx.doi.org/10.1080/2162402X.2023.2197370 |
_version_ | 1785020449122418688 |
---|---|
author | Alvarez, Maite Molina, Carmen Garasa, Saray Ochoa, Maria C. Rodriguez-Ruiz, Maria E Gomis, Gabriel Cirella, Assunta Olivera, Irene Glez-Vaz, Javier Gonzalez-Gomariz, Jose luri-Rey, carlos azpilikueta, arantza Bolaños, Elixabet Teijeira, Alvaro Berraondo, Pedro Quintero, Marisol Melero, Ignacio |
author_facet | Alvarez, Maite Molina, Carmen Garasa, Saray Ochoa, Maria C. Rodriguez-Ruiz, Maria E Gomis, Gabriel Cirella, Assunta Olivera, Irene Glez-Vaz, Javier Gonzalez-Gomariz, Jose luri-Rey, carlos azpilikueta, arantza Bolaños, Elixabet Teijeira, Alvaro Berraondo, Pedro Quintero, Marisol Melero, Ignacio |
author_sort | Alvarez, Maite |
collection | PubMed |
description | BO-112 is a poly I:C-based viral mimetic that exerts anti-tumor efficacy when intratumorally delivered in mouse models. Intratumoral BO-112 synergizes in mice with systemic anti-PD-1 mAbs and this combination has attained efficacy in PD1-refractory melanoma patients. We sought to evaluate the anti-tumor efficacy of BO-112 pre-surgically applied in neoadjuvant settings to mouse models. We have observed that repeated intratumoral injections of BO-112 prior to surgical excision of the primary tumor significantly reduced tumor metastasis from orthotopically implanted 4T1-derived tumors and subcutaneous MC38-derived tumors in mice. Such effects were enhanced when combined with systemic anti-PD-1 mAb. The anti-tumor efficacy of this neoadjuvant immunotherapy approach depended on the presence of antigen-specific effector CD8 T cells and cDC1 antigen-presenting cells. Since BO-112 has been successful in phase-two clinical trials for metastatic melanoma, these results provide a strong rationale for translating this pre-surgical strategy into clinical settings, especially in combination with standard-of-care checkpoint inhibitors. |
format | Online Article Text |
id | pubmed-10078127 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-100781272023-04-07 Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic Alvarez, Maite Molina, Carmen Garasa, Saray Ochoa, Maria C. Rodriguez-Ruiz, Maria E Gomis, Gabriel Cirella, Assunta Olivera, Irene Glez-Vaz, Javier Gonzalez-Gomariz, Jose luri-Rey, carlos azpilikueta, arantza Bolaños, Elixabet Teijeira, Alvaro Berraondo, Pedro Quintero, Marisol Melero, Ignacio Oncoimmunology Brief Report BO-112 is a poly I:C-based viral mimetic that exerts anti-tumor efficacy when intratumorally delivered in mouse models. Intratumoral BO-112 synergizes in mice with systemic anti-PD-1 mAbs and this combination has attained efficacy in PD1-refractory melanoma patients. We sought to evaluate the anti-tumor efficacy of BO-112 pre-surgically applied in neoadjuvant settings to mouse models. We have observed that repeated intratumoral injections of BO-112 prior to surgical excision of the primary tumor significantly reduced tumor metastasis from orthotopically implanted 4T1-derived tumors and subcutaneous MC38-derived tumors in mice. Such effects were enhanced when combined with systemic anti-PD-1 mAb. The anti-tumor efficacy of this neoadjuvant immunotherapy approach depended on the presence of antigen-specific effector CD8 T cells and cDC1 antigen-presenting cells. Since BO-112 has been successful in phase-two clinical trials for metastatic melanoma, these results provide a strong rationale for translating this pre-surgical strategy into clinical settings, especially in combination with standard-of-care checkpoint inhibitors. Taylor & Francis 2023-04-05 /pmc/articles/PMC10078127/ /pubmed/37035637 http://dx.doi.org/10.1080/2162402X.2023.2197370 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Brief Report Alvarez, Maite Molina, Carmen Garasa, Saray Ochoa, Maria C. Rodriguez-Ruiz, Maria E Gomis, Gabriel Cirella, Assunta Olivera, Irene Glez-Vaz, Javier Gonzalez-Gomariz, Jose luri-Rey, carlos azpilikueta, arantza Bolaños, Elixabet Teijeira, Alvaro Berraondo, Pedro Quintero, Marisol Melero, Ignacio Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic |
title | Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic |
title_full | Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic |
title_fullStr | Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic |
title_full_unstemmed | Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic |
title_short | Intratumoral neoadjuvant immunotherapy based on the BO-112 viral RNA mimetic |
title_sort | intratumoral neoadjuvant immunotherapy based on the bo-112 viral rna mimetic |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078127/ https://www.ncbi.nlm.nih.gov/pubmed/37035637 http://dx.doi.org/10.1080/2162402X.2023.2197370 |
work_keys_str_mv | AT alvarezmaite intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT molinacarmen intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT garasasaray intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT ochoamariac intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT rodriguezruizmariae intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT gomisgabriel intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT cirellaassunta intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT oliverairene intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT glezvazjavier intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT gonzalezgomarizjose intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT lurireycarlos intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT azpilikuetaarantza intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT bolanoselixabet intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT teijeiraalvaro intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT berraondopedro intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT quinteromarisol intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic AT meleroignacio intratumoralneoadjuvantimmunotherapybasedonthebo112viralrnamimetic |